Vimta Labs Limited (VIMTALABS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vimta Labs Limited (VIMTALABS) has a cash flow conversion efficiency ratio of 0.180x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs748.73 Million ≈ $8.10 Million USD) by net assets (Rs4.16 Billion ≈ $45.03 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See VIMTALABS days of operational coverage to measure how many days the company can operate on defensive assets alone.
Vimta Labs Limited - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Vimta Labs Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Vimta Labs Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vimta Labs Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Carlsmed, Inc. Common Stock
NASDAQ:CARL
|
-0.141x |
|
Cosmo Electronics Corp
TW:2466
|
-0.020x |
|
Ningbo United Group Co Ltd
SHG:600051
|
0.022x |
|
Mosel Vitelic Inc
TW:2342
|
-0.011x |
|
Papercorea
KO:001020
|
-0.054x |
|
Leonteq AG
SW:LEON
|
0.774x |
|
Evgo Inc
NASDAQ:EVGO
|
-0.100x |
|
Aurion Resources Ltd
V:AU
|
-0.009x |
Annual Cash Flow Conversion Efficiency for Vimta Labs Limited (2006–2025)
The table below shows the annual cash flow conversion efficiency of Vimta Labs Limited from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Vimta Labs Limited.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs3.79 Billion ≈ $40.97 Million |
Rs948.30 Million ≈ $10.26 Million |
0.250x | +31.42% |
| 2024-03-31 | Rs3.20 Billion ≈ $34.57 Million |
Rs608.92 Million ≈ $6.59 Million |
0.190x | -38.97% |
| 2023-03-31 | Rs2.82 Billion ≈ $30.47 Million |
Rs879.37 Million ≈ $9.51 Million |
0.312x | +23.62% |
| 2022-03-31 | Rs2.34 Billion ≈ $25.30 Million |
Rs590.69 Million ≈ $6.39 Million |
0.252x | +31.98% |
| 2021-03-31 | Rs1.94 Billion ≈ $21.02 Million |
Rs371.82 Million ≈ $4.02 Million |
0.191x | +35.82% |
| 2020-03-31 | Rs1.73 Billion ≈ $18.70 Million |
Rs243.48 Million ≈ $2.63 Million |
0.141x | -38.28% |
| 2019-03-31 | Rs1.72 Billion ≈ $18.55 Million |
Rs391.46 Million ≈ $4.23 Million |
0.228x | +4.81% |
| 2018-03-31 | Rs1.52 Billion ≈ $16.44 Million |
Rs331.05 Million ≈ $3.58 Million |
0.218x | +23.92% |
| 2017-03-31 | Rs1.36 Billion ≈ $14.72 Million |
Rs239.20 Million ≈ $2.59 Million |
0.176x | +2276.78% |
| 2016-03-31 | Rs1.26 Billion ≈ $13.64 Million |
Rs-10.18 Million ≈ $-110.07K |
-0.008x | -106.45% |
| 2015-03-31 | Rs1.22 Billion ≈ $13.23 Million |
Rs153.06 Million ≈ $1.66 Million |
0.125x | -10.34% |
| 2014-03-31 | Rs1.20 Billion ≈ $13.02 Million |
Rs168.00 Million ≈ $1.82 Million |
0.140x | +1.10% |
| 2013-03-31 | Rs1.12 Billion ≈ $12.15 Million |
Rs155.03 Million ≈ $1.68 Million |
0.138x | +16.97% |
| 2012-03-31 | Rs1.10 Billion ≈ $11.86 Million |
Rs129.39 Million ≈ $1.40 Million |
0.118x | +77.91% |
| 2011-03-31 | Rs1.25 Billion ≈ $13.52 Million |
Rs82.93 Million ≈ $896.82K |
0.066x | -64.58% |
| 2010-03-31 | Rs1.31 Billion ≈ $14.14 Million |
Rs244.77 Million ≈ $2.65 Million |
0.187x | +1.40% |
| 2009-03-31 | Rs1.30 Billion ≈ $14.07 Million |
Rs240.30 Million ≈ $2.60 Million |
0.185x | +83.97% |
| 2008-03-31 | Rs1.28 Billion ≈ $13.86 Million |
Rs128.64 Million ≈ $1.39 Million |
0.100x | +418.23% |
| 2007-03-31 | Rs1.24 Billion ≈ $13.41 Million |
Rs24.01 Million ≈ $259.70K |
0.019x | -88.04% |
| 2006-03-31 | Rs1.17 Billion ≈ $12.69 Million |
Rs189.93 Million ≈ $2.05 Million |
0.162x | -- |
About Vimta Labs Limited
Vimta Labs Limited provides contract research and testing services in India and internationally. The company offers drug discovery, development, and drug life cycle management support services in the areas of preclinical research, clinical research, and analytical services for biopharmaceutical companies; preclinical research and testing services for medical device companies; and contract researc… Read more